Related Experiment Videos
Early thrombolytic treatment reduces analgesic requirement in patients with myocardial infarction
K S Kristensen1, J Haarbo, S Munkvad
1Department of Internal Medicine, County Central Hospital, Naestved, Denmark.
Insights
Early thrombolysis with intravenous recombinant tissue-type plasminogen activator (rtPA) significantly reduced the need for pain relief in heart attack patients. rtPA treatment decreased both the duration and amount of analgesics required post-myocardial infarction.
Area of Science:
- Cardiology
- Pharmacology
- Emergency Medicine
Background:
- Myocardial infarction (heart attack) often necessitates significant pain management.
- The role of thrombolytic therapy in reducing pain post-myocardial infarction requires further investigation.
Purpose of the Study:
- To evaluate the impact of intravenous recombinant tissue-type plasminogen activator (rtPA) on analgesic requirements in patients with myocardial infarction.
- To compare the duration and dosage of analgesics needed in rtPA-treated patients versus placebo.
Main Methods:
- A randomized, double-blind trial involving 67 patients with myocardial infarction.
- Patients received either intravenous rtPA (100 mg) or placebo within 5 hours of symptom onset.
- Analgesic requirements were recorded over the subsequent 48 hours.
Main Results:
- Sixty-seven percent of rtPA-treated patients required less than 6 hours of analgesics, compared to 38% in the placebo group (P=0.04).
- The median morphine equivalent dose was significantly lower in the rtPA group (5.3 mg) versus the placebo group (11.2 mg) (P=0.04).
Conclusions:
- Early thrombolysis with intravenous rtPA appears to reduce the need for analgesic treatment in myocardial infarction patients.
- rtPA administration may alleviate pain associated with myocardial infarction, thereby decreasing analgesic consumption.
Abstract:
The duration and amount of analgesics required were investigated in 67 patients with myocardial infarction treated with intravenous recombinant tissue-type plasminogen activator (rtPA) or placebo in a randomized double-blind trial. Infusion of rtPA (100 mg)/placebo was started within 5 h after the onset of symptoms, and the requirement for analgesics during the following 48 h was recorded. Sixty-seven per cent of the 30 rtPA-treated patients required analgesic treatment for less than 6 h, compared to 38% of the 37 patients in the placebo group (P = 0.04). During the study period, patients in the rtPA group used the equivalent of 5.3 mg (median value) intravenous morphine, which was significantly less than the 11.2 mg used in the placebo group (P = 0.04). In conclusion, the present study suggests that early thrombolysis with intravenous rtPA reduces the amount and duration of analgesic treatment required by patients with myocardial infarction.